Snehal brings a confluence of early discovery, innovation and scientific expertise to her hybrid role as Spark?s Regulatory Policy Leader and Regulatory Strategy Leader for ocular programs. In this capacity she is establishing the regulatory policy function at Spark and supporting global development of gene therapies. With a keen interest in influencing gene therapy policy and shaping the regulatory framework for advanced therapies, Snehal staffs regulatory committees and task forces across the Alliance for Regenerative Medicine, BIO, and the Innovative Medicines Initiative, and is an active member of the American Society of Gene & Cell Therapy and New York Academy of Sciences. With a penchant for exploring the unexplored, she has led biology programs at both Pfizer?s Centers for Therapeutic Innovation and Johnson & Johnson?s Janssen Incubator, and founded and led a cross-functional gene therapy community of practice at JnJ. Snehal graduated summa cum laude with an AB-MA in Biology from Bryn Mawr College, and holds a Ph.D. in Molecular Genetics and Genomics from Washington University in St. Louis where she also completed the Cancer Biology pathway with the Siteman Cancer Center.